Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Lexicon Pharmaceuticals stock

LXRX
US5288723027
A14SSK

Price

1.22
Today +/-
-0.67
Today %
-46.06 %
P

Lexicon Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Lexicon Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Lexicon Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Lexicon Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Lexicon Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Lexicon Pharmaceuticals Stock Price History

DateLexicon Pharmaceuticals Price
11/1/20241.22 undefined
10/30/20241.95 undefined
10/29/20242.03 undefined
10/28/20241.86 undefined
10/25/20241.80 undefined
10/24/20241.84 undefined
10/23/20241.86 undefined
10/22/20241.94 undefined
10/21/20241.95 undefined
10/18/20242.08 undefined
10/17/20242.01 undefined
10/16/20241.91 undefined
10/15/20241.79 undefined
10/14/20241.79 undefined
10/11/20241.74 undefined
10/10/20241.69 undefined
10/9/20241.63 undefined
10/8/20241.68 undefined
10/7/20241.68 undefined

Lexicon Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Lexicon Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Lexicon Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Lexicon Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Lexicon Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Lexicon Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Lexicon Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Lexicon Pharmaceuticals’s growth potential.

Lexicon Pharmaceuticals Revenue, EBIT and net profit per share

DateLexicon Pharmaceuticals RevenueLexicon Pharmaceuticals EBITLexicon Pharmaceuticals Net Income
2029e897.7 M undefined0 undefined689.51 M undefined
2028e619.31 M undefined194.23 M undefined497.77 M undefined
2027e298.28 M undefined-70.42 M undefined8.59 M undefined
2026e123.34 M undefined-131.01 M undefined-169 M undefined
2025e51.92 M undefined-203.54 M undefined-221.11 M undefined
2024e15.81 M undefined-212.53 M undefined-253.43 M undefined
20231.2 M undefined-171.75 M undefined-177.12 M undefined
2022100,000 undefined-100.8 M undefined-101.9 M undefined
2021300,000 undefined-87.1 M undefined-87.8 M undefined
202024 M undefined-178.8 M undefined-58.6 M undefined
2019322.1 M undefined170 M undefined130.1 M undefined
201863.2 M undefined-103.3 M undefined-120.5 M undefined
201791.7 M undefined-130.6 M undefined-123 M undefined
201679.3 M undefined-127.2 M undefined-131.4 M undefined
2015130 M undefined5.1 M undefined-4.7 M undefined
201422.9 M undefined-81.7 M undefined-100.3 M undefined
20132.2 M undefined-102.4 M undefined-104.1 M undefined
20121.1 M undefined-108.4 M undefined-110.2 M undefined
20111.8 M undefined-114.1 M undefined-116.2 M undefined
20104.9 M undefined-95.7 M undefined-101.8 M undefined
200910.7 M undefined-90 M undefined-82.8 M undefined
200832.3 M undefined-96.5 M undefined-76.9 M undefined
200750.1 M undefined-75 M undefined-58.8 M undefined
200672.8 M undefined-55.2 M undefined-54.3 M undefined
200575.7 M undefined-36.1 M undefined-36.3 M undefined
200461.7 M undefined-47.5 M undefined-47.2 M undefined

Lexicon Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0012414303542617572503210411222130799163322240011551123298619897
---100.00100.00250.00114.2916.6720.0045.2422.95-4.00-30.56-36.00-68.75-60.00-75.00-100.001,000.00490.91-39.2315.19-30.77411.11-92.55---1,400.00240.00141.18142.28107.7244.91
---------------------100.0097.8095.2498.7691.67--100.00------
00000000000000000000079896031822001000000
0-2-5-8-12-35-43-62-62-47-36-55-75-96-90-95-114-108-102-815-127-130-103170-178-87-100-171-212-203-131-701940
---500.00-400.00-300.00-250.00-143.33-177.14-147.62-77.05-48.00-76.39-150.00-300.00-900.00-2,375.00-11,400.00-10,800.00-5,100.00-368.183.85-160.76-142.86-163.4952.80-741.67---17,100.00-1,413.33-398.04-106.50-23.4931.34-
0-2-5-7-13-26-35-59-64-47-36-54-58-76-82-101-116-110-104-100-4-131-123-120130-58-87-101-177-253-221-1688497689
--150.0040.0085.71100.0034.6268.578.47-26.56-23.4050.007.4131.037.8923.1714.85-5.17-5.45-3.85-96.003,175.00-6.11-2.44-208.33-144.6250.0016.0975.2542.94-12.65-23.98-104.766,112.5038.63
1.42.53.43.53.55.97.27.58.199.19.614.319.520.843.348.77073.376.3103.6103.9105.2105.8116.7110.8145.7165.7221.13000000
-----------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Lexicon Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Lexicon Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                   
19.49.2202.7149.793.6146.687.699.780258.8103.1162.1210.7281.3222.8128.7338.9521.4346.5310.8160.1271.7152.386.7138.4170.03
1.73.42.84.55.16.65.32.61.21.80.60.80.70.41.40.810.97.54.85.956.50.4001.01
0000001.10000000000000000000
00000000000000000001.94.74.20000.38
00.10.512.234.418.34.83.74.44.15.56.83.34.16.7529.110.13.94.42.75.352.22.55.13
21.112.7206166.4133.1171.598.810685.6264.7109.2169.7214.7285.8230.9134.5369532.4357.9321.9173.4337.7157.788.9140.9176.55
7.19.414.526.737.483.784.685.378.270.865.158.853.446.442.641.41.121.219.417.715.915.71.53.54.47.51
00010.400000055.7000000000000000
00000000000000000000000000
0005.44.231.80.6000053.653.653.653.653.453.453.451.950.119.70000
00025.825.825.825.825.825.825.825.825.844.544.544.544.544.544.544.544.544.544.544.544.544.544.54
0.30.30.25.21.20.2110.785.83.50.60.20.10.13.40.40.50.40.30004.50.83
7.49.714.773.568.6112.7113.2112.7104.7104.6152.488.1152.1144.7140.8139.6102.4119.5117.8114.5110.879.9464853.452.88
28.522.4220.7239.9201.7284.2212218.7190.3369.3261.6257.8366.8430.5371.7274.1471.4651.9475.7436.4284.2417.6203.7136.9194.3229.43
                                                   
29.530.100.10.10.10.10.10.10.10.10.20.30.50.50.50.70.10.10.10.10.10.10.20.20.25
0.010.010.30.330.330.380.380.380.440.670.670.730.921.091.171.181.391.41.411.441.451.461.561.611.711.86
-16.4-28.9-54.9-90.1-149.7-213.9-261.1-297.4-351.7-410.5-487.4-570.2-673.4-789.6-899.8-1,004-1,104.3-1,108.9-1,250.4-1,365.2-1,471.6-1,341.4-1,400-1,487.8-1,589.7-1,766.84
0-900-33,600-22,700-11,100-9000-10000000000-100-200-200-200010000-40031
00000000000000000000000000
20.58.2207.6218.4170166.3121.785.885.6256.3185.5163.9247.2297.9267.3171.6286.3288.6160.770.2-23.5121161.2121.1119.295.99
1.60.62.53.24.45.97.66.96.57.37.95.93.267.79.713.119.752.938.817.812.25.59.210.414.39
00.6354.24.86.96.87.39.16.65.66.313.88.97.710.124.832.112.314.542.229.710.512.414.59
1.18.24.710.612.821.119.53931.3185.70.90.20.10.10.21.676.563.440.43.4002.50.42.57
00000000000000000000000000
0.31.210004.74.80.80.9138.51.11.41.61.720.2216.314.11.11111.6000
310.611.218.821.431.838.757.545.935.321.250.910.821.318.319.345123164.7105.636.865.446.822.223.231.55
13.61.80456.332.932.231.430.529.528.527.323.521.920.287.510185.2231.6243.9234.20048.699.51
00000000000018.718.718.718.718.718.718.76600000
4002.86.629.918.743.327.416.91514.86369.446.245.836.2123.549.725.223.91.10.61.25.45.27
53.61.82.810.686.251.675.558.847.444.543.3109111.686.884.7142.4243.2153.6262.8273.8235.30.61.254104.77
814.21321.63211890.3133104.782.765.794.2119.8132.9105.1104187.4366.2318.3368.4310.6300.747.423.477.2136.32
28.522.4220.6240202284.3212218.8190.3339251.2258.1367430.8372.4275.6473.7654.8479438.6287.1421.7208.6144.5196.4232.31
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Lexicon Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Lexicon Pharmaceuticals's financial health and stability.

Assets

Lexicon Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Lexicon Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Lexicon Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Lexicon Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-5-7-12-26-35-59-64-47-36-54-71-96-93-101-116-110-104-100-4-131-123-120130-58-87-101-177
00125101112111197654421023332000
00000000000000000000-120-60000
400101031-748-20-21-16-8110-452171-53-65-44-5831-1002
000201010130079161118182212272314212458-105212326
0000000222222222116651619170210
000000000000000000000000000
0-6-9-1-18-28-7-4223-56-74-95-89-82-87-94-91-75184-175-185-148113-143-87-88-161
-1-5-4-7-13-19-4-11-11-3-1-20-1-10-10000000-1-10
-1-225-1791332-3140-1624-18815911-11370-9799-108-1171850169-1553802-71-49
0-169-1712752-2652-428-18616112-11271-97101-108-1161850169-1553803-69-49
000000000000000000000000000
103-1-340-18000036-38-3-1-182-1-2143-2-1-216-114849
32902040050104121305518116037020103600683493137
4293202-3450-1904025509114215736-1283-21149-2-2-14722142187
0000000-200420000000000000000
000000000000000000000000000
21-121-7811-2178-76214-53139-15579965-1561518-4490-62-17-23
-2-12-13.7-9.2-31.5-48.6-12.5-54.112.1-60.5-76.2-97.8-89.4-83.5-89.1-95-92.8-75.7183.9-175.8-185.6-148.7113.7-143.1-88.2-90.2-162.37
000000000000000000000000000

Lexicon Pharmaceuticals stock margins

The Lexicon Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Lexicon Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Lexicon Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Lexicon Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Lexicon Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Lexicon Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Lexicon Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Lexicon Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Lexicon Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Lexicon Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Lexicon Pharmaceuticals Margin History

Lexicon Pharmaceuticals Gross marginLexicon Pharmaceuticals Profit marginLexicon Pharmaceuticals EBIT marginLexicon Pharmaceuticals Profit margin
2029e92.94 %0 %76.81 %
2028e92.94 %31.36 %80.38 %
2027e92.94 %-23.61 %2.88 %
2026e92.94 %-106.22 %-137.02 %
2025e92.94 %-391.99 %-425.83 %
2024e92.94 %-1,344.73 %-1,603.49 %
202392.94 %-14,264.95 %-14,710.88 %
2022100 %-100,800 %-101,900 %
2021100 %-29,033.33 %-29,266.67 %
202092.08 %-745 %-244.17 %
201998.98 %52.78 %40.39 %
201896.04 %-163.45 %-190.66 %
201797.93 %-142.42 %-134.13 %
2016100 %-160.4 %-165.7 %
201592.94 %3.92 %-3.62 %
201492.94 %-356.77 %-437.99 %
201392.94 %-4,654.55 %-4,731.82 %
201292.94 %-9,854.55 %-10,018.18 %
201192.94 %-6,338.89 %-6,455.56 %
201092.94 %-1,953.06 %-2,077.55 %
200992.94 %-841.12 %-773.83 %
200892.94 %-298.76 %-238.08 %
200792.94 %-149.7 %-117.37 %
200692.94 %-75.82 %-74.59 %
200592.94 %-47.69 %-47.95 %
200492.94 %-76.99 %-76.5 %

Lexicon Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Lexicon Pharmaceuticals earnings per share therefore indicates how much revenue Lexicon Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lexicon Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lexicon Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lexicon Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lexicon Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lexicon Pharmaceuticals Revenue, EBIT and net profit per share

DateLexicon Pharmaceuticals Sales per ShareLexicon Pharmaceuticals EBIT per shareLexicon Pharmaceuticals Earnings per Share
2029e2.48 undefined0 undefined1.91 undefined
2028e1.71 undefined0 undefined1.38 undefined
2027e0.83 undefined0 undefined0.02 undefined
2026e0.34 undefined0 undefined-0.47 undefined
2025e0.14 undefined0 undefined-0.61 undefined
2024e0.04 undefined0 undefined-0.7 undefined
20230.01 undefined-0.78 undefined-0.8 undefined
20220 undefined-0.61 undefined-0.61 undefined
20210 undefined-0.6 undefined-0.6 undefined
20200.22 undefined-1.61 undefined-0.53 undefined
20192.76 undefined1.46 undefined1.11 undefined
20180.6 undefined-0.98 undefined-1.14 undefined
20170.87 undefined-1.24 undefined-1.17 undefined
20160.76 undefined-1.22 undefined-1.26 undefined
20151.25 undefined0.05 undefined-0.05 undefined
20140.3 undefined-1.07 undefined-1.31 undefined
20130.03 undefined-1.4 undefined-1.42 undefined
20120.02 undefined-1.55 undefined-1.57 undefined
20110.04 undefined-2.34 undefined-2.39 undefined
20100.11 undefined-2.21 undefined-2.35 undefined
20090.51 undefined-4.33 undefined-3.98 undefined
20081.66 undefined-4.95 undefined-3.94 undefined
20073.5 undefined-5.24 undefined-4.11 undefined
20067.58 undefined-5.75 undefined-5.66 undefined
20058.32 undefined-3.97 undefined-3.99 undefined
20046.86 undefined-5.28 undefined-5.24 undefined

Lexicon Pharmaceuticals business model

Lexicon Pharmaceuticals Inc is a biopharmaceutical company based in The Woodlands, Texas, USA. It was founded in 1995 and focuses on the discovery and development of novel drugs for the treatment of diseases that have not been adequately treated. Lexicon Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Lexicon Pharmaceuticals SWOT Analysis

Strengths

Lexicon Pharmaceuticals Inc has a strong portfolio of proprietary drug candidates, which gives them a competitive edge in the pharmaceutical industry.

The company has a highly experienced and knowledgeable management team, allowing them to make strategic decisions and navigate complex regulatory processes effectively.

Lexicon Pharmaceuticals Inc has a strong financial position, with a solid cash flow and manageable debt levels, enabling them to invest in research and development and pursue growth opportunities.

Weaknesses

The company is highly reliant on a small number of drug candidates in their pipeline, which poses a risk if any of them fail to gain regulatory approval or face significant setbacks.

Lexicon Pharmaceuticals Inc faces intense competition from both large pharmaceutical companies with significant resources and smaller biotech firms specialized in the same therapeutic areas.

The company has limited marketing and distribution capabilities, which may hinder its ability to effectively commercialize and launch new products.

Opportunities

The increasing global demand for innovative drugs presents an opportunity for Lexicon Pharmaceuticals Inc to expand its market presence and generate higher revenues.

Collaboration and partnership agreements with larger pharmaceutical companies can provide access to additional resources, expertise, and distribution channels.

Advancements in technology and genetic research open up possibilities for the development of personalized medicine, which presents a potential area for Lexicon Pharmaceuticals Inc to explore and capitalize on.

Threats

Uncertainties and challenges in the regulatory environment can delay or prevent the approval and commercialization of Lexicon Pharmaceuticals Inc's drug candidates, impacting their revenue potential.

The pharmaceutical industry is subject to rapid technological advancements and evolving market trends, which may require the company to continually adjust its strategies and offerings to remain competitive.

Growing concerns about healthcare costs and pricing pressures from payers and regulatory bodies could impact the pricing and profitability of Lexicon Pharmaceuticals Inc's products.

Lexicon Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Lexicon Pharmaceuticals historical P/E ratio, EBIT multiple, and P/S ratio

Lexicon Pharmaceuticals shares outstanding

The number of shares was Lexicon Pharmaceuticals in 2023 — This indicates how many shares 221.13 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Lexicon Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Lexicon Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Lexicon Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Lexicon Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Lexicon Pharmaceuticals stock splits

In Lexicon Pharmaceuticals's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.19 -0.17  (11.64 %)2024 Q2
3/31/2024-0.2 -0.2  (0.74 %)2024 Q1
12/31/2023-0.22 -0.2  (9.75 %)2023 Q4
9/30/2023-0.22 -0.21  (4.11 %)2023 Q3
6/30/2023-0.18 -0.22  (-23.46 %)2023 Q2
3/31/2023-0.18 -0.17  (7 %)2023 Q1
12/31/2022-0.14 -0.16  (-17.04 %)2022 Q4
9/30/2022-0.14 -0.13  (8.52 %)2022 Q3
6/30/2022-0.16 -0.16  (0.31 %)2022 Q2
3/31/2022-0.17 -0.16  (4.76 %)2022 Q1
1
2
3
4
5
...
10

Eulerpool ESG Scorecard© for the Lexicon Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

56/ 100

🌱 Environment

56

👫 Social

95

🏛️ Governance

19

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Lexicon Pharmaceuticals shareholders

%
Name
Stocks
Change
Date
47.36823 % Artal International S.C.A.171,231,426-351,7447/25/2024
10.70213 % Fidelity Management & Research Company LLC38,687,12324,793,0616/30/2024
2.48210 % BlackRock Institutional Trust Company, N.A.8,972,5501,982,9036/30/2024
2.29466 % Braidwell LP8,294,9508,294,9506/30/2024
2.12319 % The Vanguard Group, Inc.7,675,1251,273,9006/30/2024
1.61722 % OrbiMed Advisors, LLC5,846,1002,304,1006/30/2024
1.50798 % Ulys, L.L.C.5,451,20407/25/2024
1.14006 % Point72 Asset Management, L.P.4,121,1913,536,8056/30/2024
0.97270 % Invus Public Equities Advisors, LLC3,516,21407/25/2024
0.89920 % Geode Capital Management, L.L.C.3,250,535861,3986/30/2024
1
2
3
4
5
...
10

Lexicon Pharmaceuticals Executives and Management Board

Mr. Lonnel Coats(58)
Lexicon Pharmaceuticals Chief Executive Officer, Director (since 2014)
Compensation 4.17 M
Mr. Jeffrey Wade(58)
Lexicon Pharmaceuticals President, Chief Financial Officer
Compensation 1.99 M
Dr. Craig Granowitz(58)
Lexicon Pharmaceuticals Senior Vice President, Chief Medical Officer
Compensation 1.57 M
Dr. Kenneth Kassler-Taub(66)
Lexicon Pharmaceuticals Senior Vice President - Regulatory and Quality Assurance
Compensation 1.48 M
Mr. Brian Crum(49)
Lexicon Pharmaceuticals Senior Vice President, General Counsel
Compensation 1.45 M
1
2
3
4

Lexicon Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Roche Holding Stock
Roche Holding
SupplierCustomer0,240,82-0,100,20-0,23-0,17
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer-0,04-0,37-0,17-0,89-0,84-0,24
1

Most common questions regarding Lexicon Pharmaceuticals

What values and corporate philosophy does Lexicon Pharmaceuticals represent?

Lexicon Pharmaceuticals Inc is a biopharmaceutical company dedicated to improving the lives of patients through the discovery and development of innovative medicines. The company is committed to advancing the field of drug discovery and applying its expertise to bring safe and effective therapies to patients in need. Lexicon Pharmaceuticals Inc values scientific rigor, integrity, and teamwork in its pursuit of breakthrough treatments for various diseases. With a focus on cutting-edge research and development, the company aims to make a positive impact in the healthcare industry and improve the overall quality of patient care.

In which countries and regions is Lexicon Pharmaceuticals primarily present?

Lexicon Pharmaceuticals Inc is primarily present in the United States.

What significant milestones has the company Lexicon Pharmaceuticals achieved?

Lexicon Pharmaceuticals Inc. has achieved several significant milestones in its corporate history. One noteworthy milestone is the successful FDA approval of its drug, XERMELO® (telotristat ethyl), in 2017 for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy. Another notable milestone is the collaboration agreement signed with Sanofi in 2015 to develop and commercialize sotagliflozin, an investigational medicine for diabetes. Additionally, Lexicon Pharmaceuticals Inc. has achieved positive clinical trial results for many of its pipeline products, including LX2931 for rheumatoid arthritis and sotagliflozin for type 1 diabetes. These milestones demonstrate Lexicon Pharmaceuticals Inc.'s commitment to advancing healthcare and developing innovative solutions for various medical conditions.

What is the history and background of the company Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals Inc. is a renowned biopharmaceutical company that specializes in the development and commercialization of innovative treatments for various diseases. Founded in 1995, Lexicon has consistently strived to improve patient lives through its breakthrough drug discovery and research programs. With a focus on therapeutic areas such as diabetes, gastrointestinal disorders, and oncology, Lexicon's extensive pipeline boasts potential novel therapies. The company has strengthened its position through strategic collaborations and partnerships with leading pharmaceutical companies. Lexicon Pharmaceuticals Inc. continues to be at the forefront of cutting-edge medical advancements, committed to delivering effective and transformative treatments for patients worldwide.

Who are the main competitors of Lexicon Pharmaceuticals in the market?

The main competitors of Lexicon Pharmaceuticals Inc in the market include pharmaceutical companies like Novartis, Pfizer, and Eli Lilly.

In which industries is Lexicon Pharmaceuticals primarily active?

Lexicon Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Lexicon Pharmaceuticals?

The business model of Lexicon Pharmaceuticals Inc is centered around the development and commercialization of innovative therapies for critical medical needs. Lexicon focuses on discovering and advancing breakthrough treatments for a range of diseases, including diabetes, cancer, and neuropathic pain. The company utilizes its proprietary drug discovery and development platform to identify potential drug targets and develop novel small molecule drugs. Through collaborations and partnerships with pharmaceutical companies, Lexicon aims to bring its therapies to patients worldwide, improving their quality of life and addressing unmet medical needs.

What is the P/E ratio of Lexicon Pharmaceuticals 2024?

The Lexicon Pharmaceuticals P/E ratio is -1.06.

What is the P/S ratio of Lexicon Pharmaceuticals 2024?

The Lexicon Pharmaceuticals P/S ratio is 17.07.

What is the Quality Investing of Lexicon Pharmaceuticals?

The Quality Investing for Lexicon Pharmaceuticals is 3/10.

What is the revenue of Lexicon Pharmaceuticals 2024?

The expected Lexicon Pharmaceuticals revenue is 15.81 M USD.

How high is the profit of Lexicon Pharmaceuticals 2024?

The expected Lexicon Pharmaceuticals profit is -253.43 M USD.

What is the business model of Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Inc is a pharmaceutical company founded in 1995 and based in The Woodlands, Texas, USA. The company specializes in the discovery and development of medications, particularly for the treatment of metabolic disorders such as diabetes, obesity, and hyperlipidemic conditions. Lexicon Pharmaceuticals holds a variety of patents for their medical products. Lexicon consists of two main areas: research and development, and sales and marketing. The research area is responsible for the discovery and development of new molecular therapeutics, while the sales area handles marketing activities and product sales. An important milestone for Lexicon was the discovery of the SGLT1 receptor. SGLT1 is primarily active in the intestinal mucosa and influences the absorption of food. With the help of this discovery, the medication Zynquista was developed, which reduces glucose absorption in the intestine and thereby lowers blood sugar levels. Zynquista was approved by the US Food and Drug Administration (FDA) in 2019 for the treatment of type 2 diabetes. In addition to Zynquista, Lexicon also has other medications in the pipeline that can be used for the treatment of metabolic disorders. These include the medication LX9211 for the treatment of neuropathic pain, the medication Sotagliflozin for the treatment of type 1 diabetes, and the medication LX2761 for the treatment of type 2 diabetes. In late 2021, Lexicon Pharmaceuticals entered into a partnership agreement with Sanofi to jointly sell the medication Sotagliflozin in Europe. Sanofi will be responsible for the marketing and distribution of the medication. Lexicon also operates a program called "Partners in Progress" aimed at organizations engaged in research and development in the field of metabolic disorders. Through this program, Lexicon offers a range of collaboration opportunities to advance the development of new therapies and treatment methods. Overall, Lexicon Pharmaceuticals Inc is an innovative and advanced company specializing in the discovery and development of medications for the treatment of metabolic disorders. With its research and development of new medications and collaboration with partners in the field of metabolic disorders, the company is well-positioned to continue playing an important role in the pharmaceutical industry.

What is the Lexicon Pharmaceuticals dividend?

Lexicon Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Lexicon Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Lexicon Pharmaceuticals or the company does not pay out a dividend.

What is the Lexicon Pharmaceuticals ISIN?

The ISIN of Lexicon Pharmaceuticals is US5288723027.

What is the Lexicon Pharmaceuticals WKN?

The WKN of Lexicon Pharmaceuticals is A14SSK.

What is the Lexicon Pharmaceuticals ticker?

The ticker of Lexicon Pharmaceuticals is LXRX.

How much dividend does Lexicon Pharmaceuticals pay?

Over the past 12 months, Lexicon Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Lexicon Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Lexicon Pharmaceuticals?

The current dividend yield of Lexicon Pharmaceuticals is .

When does Lexicon Pharmaceuticals pay dividends?

Lexicon Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Lexicon Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Lexicon Pharmaceuticals located?

Lexicon Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Lexicon Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Lexicon Pharmaceuticals from 11/5/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/5/2024.

When did Lexicon Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/5/2024.

What was the dividend of Lexicon Pharmaceuticals in the year 2023?

In the year 2023, Lexicon Pharmaceuticals distributed 0 USD as dividends.

In which currency does Lexicon Pharmaceuticals pay out the dividend?

The dividends of Lexicon Pharmaceuticals are distributed in USD.

All fundamentals about Lexicon Pharmaceuticals

Our stock analysis for Lexicon Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Lexicon Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.